BMEA

Biomea Fusion, Inc.

• TipRanks·1d ago

  Biomea Fusion presents Phase II Covalent-111 data in Type 2 Diabetes

• Reuters·2d ago

  Biomea Fusion reports Phase II COVALENT-111 data showing 1% HbA1c reduction at Week 52 with icovamenib in type 2 diabetes patients

• TipRanks·03/04 15:46

  Biomea Fusion management to meet virtually with Craig-Hallum

• TipRanks·02/25 11:32

  Biomea Fusion Updates Corporate Presentation on Metabolic Pipeline

• Reuters·02/19 12:01

  Biomea Fusion to Present at Oppenheimer Healthcare Life Sciences Conference

• Seeking Alpha·01/23 16:24

  JPMorgan’s top short ideas for Q1: FTNT, TXT, IMO and more

• TipRanks·01/14 21:37

  Biomea Fusion Highlights Diabetes Pipeline at JPM Conference

• TipRanks·01/13 20:20

  Biomea Fusion initiated with a Buy at Rodman & Renshaw

• Dow Jones·01/13 12:49

  Biomea Fusion Is Maintained at Buy by D. Boral Capital

• Dow Jones·01/13 12:49

  Biomea Fusion Price Target Maintained With a $12.00/Share by D. Boral Capital

• TipRanks·01/13 11:48

  H.C. Wainwright Sticks to Its Buy Rating for Biomea Fusion (BMEA)

• TipRanks·01/12 13:40

  Biomea Fusion enters 2026 focused on icovamenib, BMF-650 milestones

• Reuters·01/12 13:00

  Biomea Fusion Inc. Announces 2026 Strategy Focusing on Advancing Icovamenib and BMF-650 Clinical Programs, Initiating Phase II Trials in Type 2 Diabetes and Continuing Oral GLP-1 Candidate Development

• Reuters·12/17/2025 12:00

  Biomea Fusion to Present at J.P. Morgan Healthcare Conference

• TipRanks·12/16/2025 02:10

  Top Executive Makes Bold Move with Major Stock Purchase in Biomea Fusion